Bluejay diagnostics, inc. appoints mark feinberg, m.d. as chief medical advisor

Acton, mass., jan. 05, 2022 (globe newswire) -- bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of mark w. feinberg, m.d. as chief medical advisor. dr. feinberg will guide bluejay's clinical development programs and provide strategic medical and scientific leadership to the company.
BJDX Ratings Summary
BJDX Quant Ranking